Concepedia

Hepatic Function-based Dosing

Hepatic Function-Based Dosing is a dosing strategy that adjusts medication administration according to an individual’s hepatic function, accounting for impaired drug metabolism and clearance in patients with liver dysfunction.

62

Publications

3.2K

Citations

397

Authors

173

Institutions

Publications per year

2017–2026

12

Variants

Hepatic Dosing

Parents

Publications

62

Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction

Roger K. Verbeeck · European Journal of Clinical Pharmacology · 2008 · 638 citations

, , +14

Safety and Pharmacokinetics of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma

Masafumi Ikeda, Takuji Okusaka, Shuichi Mitsunaga et al. · Clinical Cancer Research · 2015 · 189 citations

, , +16

Phase I Study of Vorinostat in Patients With Advanced Solid Tumors and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study

Suresh S. Ramalingam, Shivaani Kummar, John Sarantopoulos et al. · Journal of Clinical Oncology · 2010 · 103 citations

, , +16

When "enough" is not enough: new perspectives on optimal methadone maintenance dose.

Sarah Leavitt, Marc Shinderman, Simon Maxwell et al. · PubMed · 2000 · 102 citations

, , +16

Effect of hepatic dysfunction and T tube clamping on FK 506 pharmacokinetics and trough concentrations.

Ashokkumar Jain, Raman Venkataramanan, Evan M. Cadoff et al. · PubMed · 1990 · 98 citations

, , +15

1–5 of 62

Authors

397

  1. SP
    S. Percy Ivy

    National Cancer Institute, United States

    5 publications · 343 citations

    5

    h-index

  2. CP
    Chandra P. Belani

    UPMC Hillman Cancer Center, United States

    4 publications · 287 citations

    4

    h-index

  3. DM
    Daniel Mulkerin

    University of Wisconsin Carbone Cancer Center, United States

    4 publications · 247 citations

    4

    h-index

  4. AH
    Anne Hamilton

    Peter MacCallum Cancer Centre, Australia

    3 publications · 229 citations

    3

    h-index

  5. KC
    Kenneth C. Lasseter

    Clinical Research Associates, United States

    3 publications · 121 citations

    3

    h-index

1–5 of 397

Institutions

173

  1. Pfizer (United States)

    New York, United States

    6 h-index

    31 publications

    1.3K citations

  2. The Barbara Ann Karmanos Cancer Institute

    Detroit, United States

    4 h-index

    48 publications

    3.6K citations

  3. National Cancer Institute

    Bethesda, United States

    4 h-index

    46 publications

    2.9K citations

  4. City of Hope

    Lancaster, United States

    4 h-index

    57 publications

    3.8K citations

  5. UPMC Hillman Cancer Center

    Pittsburgh, United States

    4 h-index

    45 publications

    3.8K citations

  6. University of Maryland, Baltimore

    Baltimore, United States

    3 h-index

    8 publications

    192 citations

  7. Clinical Research Associates

    Nashville, United States

    3 h-index

    4 publications

    187 citations

  8. Pfizer (France)

    Paris, France

    3 h-index

    4 publications

    140 citations

1–8 of 173

Venues

  1. The Journal of Clinical Pharmacology

    9 publications · 350 citations

    9

    h-index

  2. PubMed

    Repository · 6 publications · 409 citations

    6

    h-index

  3. Journal of Clinical Oncology

    5 publications · 336 citations

    5

    h-index

  4. Clinical Cancer Research

    3 publications · 327 citations

    3

    h-index

  5. European Journal of Clinical Pharmacology

    3 publications · 736 citations

    3

    h-index

1–5